| Carla Ximena Torres-zegarra, MD | |
|
13123 E 16th Ave # B570, Aurora, CO 80045-7106 | |
| (720) 777-1421 | |
| Not Available |
| Full Name | Carla Ximena Torres-zegarra |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 18 Years |
| Location | 13123 E 16th Ave # B570, Aurora, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346470143 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Children's Hospital Colorado | Aurora, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Physicians Incorporated | 3476465667 | 2657 |
News Archive
Scientists at the research centre MEMBRANES at Aarhus University, Denmark, have completed an old puzzle, which since the 60s from many sides has been regarded as impossible to complete. The challenge was to solve the structure of the protecting protein complex that forms when haemoglobin is released from red cells and becomes toxic. This toxic release of haemoglobin occurs in many diseases affecting red cell stability, e.g. malaria.
A new study has shown that including nuts in daily diet could significantly improve the quality as well as function of the human sperm. Nuts are part of the Mediterranean diet that is considered to be the healthiest diet for the heart, blood vessels and other organs.
IVAX Diagnostics, Inc. announced today that its U.S. subsidiary headquartered in Florida, Diamedix Corporation, has filed a 510(k) premarket submission with the U.S. Food and Drug Administration ("FDA") for its next -generation fully automated Enzyme-linked Immunosorbent Assay ("ELISA") system for autoimmune and infectious disease testing, named the Mago®4S.
German researchers have discovered five biomarkers that may predict the progression of structural damage in the spine of patients with ankylosing spondylitis who are already at high risk for disease progression.
MELA Sciences, Inc., designer and developer of MelaFind®, an FDA and CE Mark approved non-invasive optical device that assists dermatologists in diagnosing melanoma at its most curable stage, participated in a two-day hands-on skin cancer diagnostics workshop in Augsburg, Germany, where leading dermatologists examined "high-risk" melanoma patients with MelaFind® and also participated in an imaging devices exhibit.
› Verified 4 days ago
| Entity Name | Denver Health And Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477569838 PECOS PAC ID: 4688583578 Enrollment ID: O20031105000211 |
News Archive
Scientists at the research centre MEMBRANES at Aarhus University, Denmark, have completed an old puzzle, which since the 60s from many sides has been regarded as impossible to complete. The challenge was to solve the structure of the protecting protein complex that forms when haemoglobin is released from red cells and becomes toxic. This toxic release of haemoglobin occurs in many diseases affecting red cell stability, e.g. malaria.
A new study has shown that including nuts in daily diet could significantly improve the quality as well as function of the human sperm. Nuts are part of the Mediterranean diet that is considered to be the healthiest diet for the heart, blood vessels and other organs.
IVAX Diagnostics, Inc. announced today that its U.S. subsidiary headquartered in Florida, Diamedix Corporation, has filed a 510(k) premarket submission with the U.S. Food and Drug Administration ("FDA") for its next -generation fully automated Enzyme-linked Immunosorbent Assay ("ELISA") system for autoimmune and infectious disease testing, named the Mago®4S.
German researchers have discovered five biomarkers that may predict the progression of structural damage in the spine of patients with ankylosing spondylitis who are already at high risk for disease progression.
MELA Sciences, Inc., designer and developer of MelaFind®, an FDA and CE Mark approved non-invasive optical device that assists dermatologists in diagnosing melanoma at its most curable stage, participated in a two-day hands-on skin cancer diagnostics workshop in Augsburg, Germany, where leading dermatologists examined "high-risk" melanoma patients with MelaFind® and also participated in an imaging devices exhibit.
› Verified 4 days ago
| Entity Name | University Physicians Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962461889 PECOS PAC ID: 3476465667 Enrollment ID: O20031105000375 |
News Archive
Scientists at the research centre MEMBRANES at Aarhus University, Denmark, have completed an old puzzle, which since the 60s from many sides has been regarded as impossible to complete. The challenge was to solve the structure of the protecting protein complex that forms when haemoglobin is released from red cells and becomes toxic. This toxic release of haemoglobin occurs in many diseases affecting red cell stability, e.g. malaria.
A new study has shown that including nuts in daily diet could significantly improve the quality as well as function of the human sperm. Nuts are part of the Mediterranean diet that is considered to be the healthiest diet for the heart, blood vessels and other organs.
IVAX Diagnostics, Inc. announced today that its U.S. subsidiary headquartered in Florida, Diamedix Corporation, has filed a 510(k) premarket submission with the U.S. Food and Drug Administration ("FDA") for its next -generation fully automated Enzyme-linked Immunosorbent Assay ("ELISA") system for autoimmune and infectious disease testing, named the Mago®4S.
German researchers have discovered five biomarkers that may predict the progression of structural damage in the spine of patients with ankylosing spondylitis who are already at high risk for disease progression.
MELA Sciences, Inc., designer and developer of MelaFind®, an FDA and CE Mark approved non-invasive optical device that assists dermatologists in diagnosing melanoma at its most curable stage, participated in a two-day hands-on skin cancer diagnostics workshop in Augsburg, Germany, where leading dermatologists examined "high-risk" melanoma patients with MelaFind® and also participated in an imaging devices exhibit.
› Verified 4 days ago
| Entity Name | Advanced Dermatology Skin Cancer & Laser Surgery Center P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134170012 PECOS PAC ID: 6709775133 Enrollment ID: O20040313000244 |
News Archive
Scientists at the research centre MEMBRANES at Aarhus University, Denmark, have completed an old puzzle, which since the 60s from many sides has been regarded as impossible to complete. The challenge was to solve the structure of the protecting protein complex that forms when haemoglobin is released from red cells and becomes toxic. This toxic release of haemoglobin occurs in many diseases affecting red cell stability, e.g. malaria.
A new study has shown that including nuts in daily diet could significantly improve the quality as well as function of the human sperm. Nuts are part of the Mediterranean diet that is considered to be the healthiest diet for the heart, blood vessels and other organs.
IVAX Diagnostics, Inc. announced today that its U.S. subsidiary headquartered in Florida, Diamedix Corporation, has filed a 510(k) premarket submission with the U.S. Food and Drug Administration ("FDA") for its next -generation fully automated Enzyme-linked Immunosorbent Assay ("ELISA") system for autoimmune and infectious disease testing, named the Mago®4S.
German researchers have discovered five biomarkers that may predict the progression of structural damage in the spine of patients with ankylosing spondylitis who are already at high risk for disease progression.
MELA Sciences, Inc., designer and developer of MelaFind®, an FDA and CE Mark approved non-invasive optical device that assists dermatologists in diagnosing melanoma at its most curable stage, participated in a two-day hands-on skin cancer diagnostics workshop in Augsburg, Germany, where leading dermatologists examined "high-risk" melanoma patients with MelaFind® and also participated in an imaging devices exhibit.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carla Ximena Torres-zegarra, MD Po Box 110429, Aurora, CO 80042-0429 Ph: (303) 493-7000 | Carla Ximena Torres-zegarra, MD 13123 E 16th Ave # B570, Aurora, CO 80045-7106 Ph: (720) 777-1421 |
News Archive
Scientists at the research centre MEMBRANES at Aarhus University, Denmark, have completed an old puzzle, which since the 60s from many sides has been regarded as impossible to complete. The challenge was to solve the structure of the protecting protein complex that forms when haemoglobin is released from red cells and becomes toxic. This toxic release of haemoglobin occurs in many diseases affecting red cell stability, e.g. malaria.
A new study has shown that including nuts in daily diet could significantly improve the quality as well as function of the human sperm. Nuts are part of the Mediterranean diet that is considered to be the healthiest diet for the heart, blood vessels and other organs.
IVAX Diagnostics, Inc. announced today that its U.S. subsidiary headquartered in Florida, Diamedix Corporation, has filed a 510(k) premarket submission with the U.S. Food and Drug Administration ("FDA") for its next -generation fully automated Enzyme-linked Immunosorbent Assay ("ELISA") system for autoimmune and infectious disease testing, named the Mago®4S.
German researchers have discovered five biomarkers that may predict the progression of structural damage in the spine of patients with ankylosing spondylitis who are already at high risk for disease progression.
MELA Sciences, Inc., designer and developer of MelaFind®, an FDA and CE Mark approved non-invasive optical device that assists dermatologists in diagnosing melanoma at its most curable stage, participated in a two-day hands-on skin cancer diagnostics workshop in Augsburg, Germany, where leading dermatologists examined "high-risk" melanoma patients with MelaFind® and also participated in an imaging devices exhibit.
› Verified 4 days ago
Robert Dellavalle, MD Dermatology Medicare: Medicare Enrolled Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Theresa Pacheco, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Dr. Anthony Christos Parris, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Sean T Amsbaugh, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1390 S Potomac St, Suite 124, Aurora, CO 80012 Phone: 303-368-8611 Fax: 303-368-9791 | |
Dr. Stanca Ariana Birlea, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0500 Fax: 720-848-0538 | |
Mariah Brown, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1665 Aurora Ct Rm 3004, Aurora, CO 80045 Phone: 720-848-0504 | |
Grant Russell Plost, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 |